Metsera Reports Highly Competitive Results from Ongoing Trial …
WEB3 days ago · NEW YORK, September 24, 2024--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive ...
News - Metsera
WEBNews. 4.18.2024. Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases. Read More . Advancing a broad portfolio designed to accelerate innovation and shape the future of treatment for weight loss, obesity-related conditions and metabolic diseases.
Metsera Reports Highly Competitive Results from Ongoing Trial …
WEB2 days ago · Metsera launching Phase 2b trials in Q4 2024, with data anticipated in first half of 2025 Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 clinical trial of MET-097, an ultra long-acting injectable ...
Readout Newsletter: Metsera, Novo Nordisk, Bluebird Bio updates …
WEB2 days ago · Metsera’s GLP-1 drug has potential for monthly dosing. This morning, Metsera, a new obesity biotech, reported that its GLP-1 drug led to substantial and durable weight loss in a Phase 1 study ...
New Weight Loss Biotech Metsera Stuns with 7.5% Weight Loss
WEB2 days ago · Five months after launching, Metsera is making waves with Phase I results for a long-acting GLP-1 injectable showing a 7.5% reduction in body weight at day 36. The biotech said the results were as good as or better than approved or other similar clinical-stage GLP-1 compounds out there now. ... BioSpace is …
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
WEB3 days ago · Obesity drug startup Metsera on Tuesday reported its first clinical data since launching in April with $290 million in venture funding. The data come from a Phase 1 trial of a drug, MET-097, that ...
Metsera
WEBMetsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases. ABOUT NEWS
Metsera Launches to Lead the Next Generation of Medicines for …
WEBApr 18, 2024 · Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...
Metsera Reports Highly Competitive Results from Ongoing Trial …
WEB1 day ago · Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future ...
Metsera comes out of stealth with $290 million for obesity drugs
WEBApr 18, 2024 · Metsera came out of stealth mode Thursday with $290 million in seed and Series A financing. ARCH and Population Health Partners, which launched in 2020 and has several veterans from Pfizer and...
Skip to content